Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

Stopped early · Phase 2

Conditions studied: Colorectal Neoplasms

In brief

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Key facts

Study ID

NCT00051688

Run by

Chiron Corporation

Starts

2003-06-01

Expected to finish

2004-08-01

Last updated by the study team

2006-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• ACRC/Arizona Clinical Research Center — Tucson, Arizona, United States
• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Comprehensive Cancer Centers of the Desert — Palm Springs, California, United States
• Cancer Institute Medical Group — Santa Monica, California, United States
• Georgetown University Medical Center, Lombardi Cancer Center — Washington D.C., District of Columbia, United States
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
• Kansas City Oncology and Hematology Group — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.